Needham Maintains Buy on Axsome Therapeutics, Raises Price Target to $268

Axsome Therapeutics, Inc.

Axsome Therapeutics, Inc.

AXSM

0.00

Needham analyst Ami Fadia maintains Axsome Therapeutics (NASDAQ: AXSM) with a Buy and raises the price target from $267 to $268.